Enhanced cytotoxicity with a novel system combining the paclitaxel-2′-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus

Cancer Letters

Volumn 288, Issue 1, 2010, Pages 17-27

  Ishida, Daisuke ^a   Nawa, Akihiro ^a   Tanino, Tadatoshi ^b   Goshima, Fumi ^a   Luo, Chen Hong ^a   Iwaki, Masahiro ^b   Kajiyama, Hiroaki ^a   Shibata, Kiyosumi ^a   Yamamoto, Eiko ^a   Ino, Kazuhiko ^a   Tsurumi, Tatsuya ^c   Nishiyama, Yukihiro ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Carboxylesterase (CES); Gene directed enzyme prodrug therapy (GDEPT); HSV amplicon; Oncolytic virus HSV 1 HF10; Paclitaxel 2 ethylcarbonate prodrug (TAX 2 Et)

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; GREEN FLUORESCENT PROTEIN; ONCOLYTIC HERPES VIRUS; PACLITAXEL 2' ETHYLCARBONATE; PRODRUG; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ARTICLE; CANCER GENE THERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOXYLESTERASE; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HELA CELLS; HERPESVIRUS 1, HUMAN; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PACLITAXEL; PRODRUGS; RABBITS; TIME FACTORS; TRANSFECTION; VERO CELLS;

HUMAN HERPESVIRUS 1; MUS; ORYCTOLAGUS CUNICULUS; REPLICATION COMPETENT VIRUSES; SIMPLEXVIRUS;

EID: 73649135058     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.014     Document Type: Article

References (47)

1. Takakuwa H., Goshima F., Nozawa N., Yoshikawa T., Kimata H., Nakao A., et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. 148 (2003) 813-825
2. Kohno S., Lou C., Goshima F., Nishiyama Y., Sata T., and Ono Y. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer. Urology 66 (2005) 1116-1121
3. Watanabe D., Goshima F., Mori I., Tamada Y., Matsumoto Y., and Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J. Dermatol. Sci. 50 (2008) 185-196
4. Nawa A., Luo C., Zhang L., Ushijima Y., Ishida D., Kamakura M., et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF10: applications for cancer gene therapy. Curr. Gene. Ther. 8 (2008) 208-221
5. Shimoyama S., Goshima F., Teshigahara O., Kasuya H., Kodera Y., Nakao A., et al. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepatogastroenterology 54 (2007) 1038-1042
6. Nawa A., Tanino T., Lou C., Iwaki M., Kajiyama H., Shibata K., et al. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?. Anti-Cancer Agents Med. Chem. 8 (2008) 232-239
7. Ichikawa T., and Chiocca E.A. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res. 61 (2001) 5336-5339
8. Chiocca E.A. Oncolytic viruses. Nat. Rev. Cancer 2 (2002) 938-950
9. Parato K.A., Senger D., Forsyth P.A., and Bell J.C. Recent progress in the battle between oncolytic viruses and tumors. Nat. Rev. Cancer 5 (2005) 965-976
10. Liu T.C., and Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of concept and future directions. Cancer Res. 67 (2007) 429-432
11. Kimata H., Takakuwa H., Goshima F., Teshigawara O., Nakao A., Kurata T., et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex virus. Hepatogastroenterology 50 (2003) 961-966
12. Kimata H., Imai T., Kikumori T., Teshigawara O., Nagasaka T., Goshima F., et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann. Surg. Oncol. 13 (2006) 1078-1084
13. Nakao A., Kimata H., Imai T., Kikumoto T., Teshigawara O., Nagasaka T., et al. Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer. Ann. Oncol. 15 (2004) 988-989
14. Fujimoto Y., Mizuno T., Sugiura S., Goshima F., Kohno S., Nakashima T., et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 126 (2006) 1115-1117
15. Kambara H., Saeki Y., and Chiocca E.A. Cyclophosphamide allows for in vivo does reduction of a potent oncolytic virus. Cancer Res. 65 (2005) 11255-11258
16. Eisenberg D.P., Adusumilli P.S., Hendershott K.J., Yu Z., Mullerad M., Chan M.K., et al. 5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J. Gasterointest. Surg. 9 (2005) 1068-1079
17. Aghi M., Rabikin S., and Martuza R.L. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl. Cancer. Inst. 98 (2006) 38-50
18. Lin S.F., Gao S.P., Price D.L., Li S., Chou T.C., Singh P., et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin. Cancer Res. 14 (2008) 1519-1528
19. Nakamura H., Mullen J.T., Chadrasekhar S., Pawlik T.M., Yoon S.S., and Tanabe K.K. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res. 61 (2001) 5447-5452
20. Pawlik T.M., Nakamura H., Mullen J.T., Kasuya H., Yoon S.S., Chandrasekhar S., et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 95 (2002) 1171-1181
21. Wierdl M., Morton C.L., Weeks J.K., Danks M.K., Harris L.C., and Potter P.M. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 61 (2001) 5078-5082
22. Stubdal H., Perin N., Lemmon M., Holman P., Bauzon M., Potter P.M., et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res. 63 (2003) 6900-6908
23. Oosterhoff D., Witlox M.A., van Beusechem V.W., Haisma H.J., Schaap G.R., Bras J., et al. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol. Cancer Ther. 2 (2003) 765-771
24. William P., and McGuire III. Current status of taxane and platinum-based chemotherapy in ovarian cancer. J. Clin. Oncol. 21 (2003) 133s-135s
25. Markman M. Taxanes in the management of gynecologic malignancies. Expert Rev. Anticancer Ther. 8 (2008) 219-226
26. Magri N.F., and Kingston D.G. Modified taxol. 2. Oxidation products of taxol. J. Org. Chem. 51 (1986) 797-802
27. Ueda Y., Wong H., Matiskella J.D., Mikkilineni A.B., Farina V., Fairchild C., et al. Synthesis and antitumor elevation of 2′-oxycarbonylpaclitaxels (paclitaxel-2′-carbonates). Bioorg. Med. Chem. 4 (1994) 1861-1864
28. Tanino T., Nawa A., Kondo E., Kikkawa F., Daikoku T., Tsurumi T., et al. Paclitaxel-2′-ethylcarbonate prodrug can circumvent P-glycoprotein-mediated cellular efflux to increase drug cytotoxicity. Pharm. Res. 24 (2007) 555-565
29. Hennebelle I., Terret C., Chatelut E., Bugat R., Canal P., and Guichard S. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Anti-cancer Drug 11 (2000) 456-470
30. Spaete R.R., and Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30 (1982) 295-304
31. Sena-Esteves M., Saeki Y., Fraefel C., and Breakefield X.O. HSV-1 amplicon vectors-simplicity and versatility. Mol. Ther. 2 (2000) 9-15
32. Wang Y., Mukherjee S., Fraefel C., Breakefield X.O., Allen P.D., et al. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Human Gene Ther. 13 (2002) 261-273
33. Saeki Y., Fraefel C., Ichikawa T., Breakefield X.O., and Chiocca E.A. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol. Ther. 3 (2001) 591-601
34. Yoon K.J., Hyatt J.L., Morton C.L., Lee R.E., Potter P.M., and Danks M.K. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Mol. Cancer Ther. 3 (2004) 903-909
35. Humerickhouse R., Lohrbach K., Li L., Bosron W.F., and Dolan M.E. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60 (2000) 1189-1192
36. Danks M.K., Morton C.L., Krull E.J., Cheshire P.J., Richmond L.B., Naeve C.W., et al. Comparison of activation of CTP-11 by rabbit and human carboxylesterase for use in enzyme/prodrug therapy. Clin. Cancer. Res. 5 (1999) 917-924
37. Potter P.M., Pawlik C.A., Morton C.L., Naeve C.W., and Danks M.K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activatives the prodrug irinotecan (CPT-11). Cancer Res. 58 (1998) 2646-2651
38. Wierdl M., Wall A., Morton C.L., Sampath J., Danks M.K., Schuetz J.D., et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol. Pharmacol. 64 (2003) 279-288
39. Zhang L., Daikoku T., Ohtake K., Ohtsuka J., Nawa A., Kudoh A., et al. HSV-1 HF10. J. Virol Methods 137 (2006) 177-183
40. Roizman B., and Knipe D.M. Herpes simplex viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology (2001), Lippincott Williams & Wilkins, Philadelphia 2399-2460
41. Schepelmann S., Hallenbeck P., Ogilvie L.M., Hedley D., Friedlos F., Martin J., et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 65 (2005) 5003-5008
42. Petrowsky H., Roberts G.D., Kooby D.A., Burt B.M., Bennett J.J., Delman K.A., et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J. Virol. 75 (2001) 7050-7058
43. Bennett J.J., Adusumilli P., Petrowsky H., Burt B.M., Roberts G., Delman K.A., et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma1 34.5 deleted oncolytic herpes virus (G207). FASEB J. 18 (2004) 1001-1003
44. Kotsakis A., Pomeranz L.E., Blouin A., and Blaho J.A. Microtuble reorganization during herpes simplex virus type 1 infection facilitates the nuclear locarization of VP22, a major virion tegment protein. J. Virol. 75 (2001) 8697-8711
45. Nagano S., Perentes J.Y., Jain R.K., and Boucher Y. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res. 68 (2008) 3795-3802
46. Morton C.L., Wierdl M., Oliver L., Ma M.K., Danks M.K., Stewart C.F., et al. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res. 60 (2000) 4206-4210
47. Rivory L.P., Haaz M.C., Canal P., Lokiec F., Armand J.P., and Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res. 3 (1997) 1261-1266